Amylin Pharmaceuticals Inc. (AMLN)

[surf1944]

7:10AM Amylin Pharma, Eli Lilly (LLY), and Alkermes (ALKS) announced positive analyses from the DURATION-3 and -4 trials (AMLN) 10.63 : Cos announced that patients treated with the investigational medication BYDUREON experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients receiving BYDUREON for the treatment of type 2 diabetes experienced improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels.